Fludarabine
Systemic-Onset Juvenile Idiopathic Arthritis
Paul SzabolcsSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Systemic-Onset Juvenile Idiopathic Arthritis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 1.BETA.) (HUMAN CLONE ACZ885 HEAVY CHAIN V REGION) Novartis Pharmaceuticals | Phase 3 | BB |
Pneumo23 Institut National de la Santé Et de la Recherche Médicale, France | Phase 2/3 | B |
Anakinra Institut National de la Santé Et de la Recherche Médicale, France | Phase 2/3 | B |
Alemtuzumab Paul Szabolcs | Phase 2 | CCC |
Hydroxyurea Paul Szabolcs | Phase 2 | CCC |
Thiotepa Paul Szabolcs | Phase 2 | CCC |
Melphalan Paul Szabolcs | Phase 2 | CCC |
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative · Phase 2
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →